Journal
THERANOSTICS
Volume 12, Issue 2, Pages 891-909Publisher
IVYSPRING INT PUBL
DOI: 10.7150/thno.62685
Keywords
Osteoarthritis; microfluidics; organ-on-a-chip; biosensor; intra-articular injection
Categories
Funding
- Health and Medical Research Fund Scheme [01150087, 16172691]
- Research Grants Council of Hong Kong ECS [PolyU 251008/18M]
- GRF [PolyU 151061/20M, PolyU15100821M]
- NFSC/RGC schemes [N_PolyU 520/20]
- ITF MHKJFS [MHP/011/20]
- Hong Kong Polytechnic University Project of Strategic Importance (ZE2C)
- Brigham Research Institute
Ask authors/readers for more resources
This article introduces the application of microfluidic technology in the treatment of osteoarthritis (OA). OA is a prevalent degenerative joint disease with no effective treatment currently available. Microfluidic technology is considered a promising approach for OA modeling and drug screening, early diagnosis, and clinical therapy.
Osteoarthritis (OA) is a prevalent debilitating age-related joint degenerative disease. It is a leading cause of pain and functional disability in older adults. Unfortunately, there is no cure for OA once the damage is established. Therefore, it promotes an urgent need for early detection and intervention of OA. Theranostics, combining therapy and diagnosis, emerges as a promising approach for OA management. However, OA theranostics is still in its infancy. Three fundamental needs have to be firstly fulfilled: i) a reliable OA model for disease pathogenesis investigation and drug screening, ii) an effective and precise diagnostic platform, and iii) an advanced fabrication approach for drug delivery and therapy. Meanwhile, microfluidics emerges as a versatile technology to address each of the needs and eventually boost the development of OA theranostics. Therefore, this review focuses on the applications of microfluidics, from benchtop to bedside, for OA modelling and drug screening, early diagnosis, and clinical therapy. We first introduce the basic pathophysiology of OA and point out the major unfilled research gaps in current OA management including lack of disease modelling and drug screening platforms, early diagnostic modalities and disease-modifying drugs and delivery approaches. Accordingly, we then summarize the state-of-the-art microfluidics technology for OA management from in vitro modelling and diagnosis to therapy. Given the existing promising results, we further discuss the future development of microfluidic platforms towards clinical translation at the crossroad of engineering and biomedicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available